Tiziana Life Sciences Plc, a 2013 spin-out from Cardiff University, has appointed Napoleone Ferrara, a prominent US scientist, as chairman of its new scientific advisory board and consultant to the company.
Tiziana was created to exploit intellectual property in the field of oncology. Developed by scientists at Cardiff University, the technology focuses on targeting the product of the B-cell lymphoma 3 gene, the inhibition of which affects the ability of a cancer cell to migrate. The company’s lead product is directed at metastatic breast cancer.
Dr Ferrara is senior deputy director for basic sciences at the University of California’s Moores Cancer Center in San Diego and a professor of pathology at the School of Medicine. He is credited with research that led to the development of Avastin (bevacizumab), a drug approved for colorectal cancer and other indications.
Tiziana recently obtained a listing on London’s Alternative Investment Market by a reverse takeover of Alexander David Investments Plc.
Copyright 2014 Evernow Publishing Ltd